A north-south divide threatens to emerge in multiple myeloma in the UK, after the Scottish Medicines Consortium (SMC) backed NHS use of two drugs previously turned down by NICE in England.<
Shares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug omecamtiv mecarbil disappointed in a large phase 3 trial.
Last year Amgen intrigued scientists and investors alike after announcing data showing it had produced the first drug that seemed to work against KRAS mutations, which are found in lung and
Amgen has scored yet another home run in the US courts, this time seeing off a legal challenge from Genentech, which was trying to block it from launching two cut-price cancer biosimilars.
Amgen’s reputation as a fearsome adversary in the courtroom remains intact after it won the latest round in a legal tussle with Sandoz over the patent covering the blockbuster inflammatory